8-K: InMed Pharmaceuticals Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals announced its Q3 fiscal year 2025 financial results, highlighting progress in its Alzheimer's and AMD programs and stable revenue from BayMedica.

Summary

• InMed Pharmaceuticals reported a net loss of $2.12 million for the three months ended March 31, 2025, compared to a net loss of $1.72 million for the same period last year.
• The increase in net loss was primarily driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs.
• Pharmaceutical research and development and patent expenses were $0.91 million for the three months ended March 31, 2025, compared with $0.65 million for the three months ended March 31, 2024.
• General and administrative expenses decreased to $1.33 million for the three months ended March 31, 2025, from $3.75 million in the same period the previous year.
• As of March 31, 2025, the Company's cash, cash equivalents and short-term investments were $4.68 million, compared to $6.57 million at June 30, 2024.
• The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the third quarter of calendar year 2025.
• BayMedica's commercial business generated revenues of $1.26 million for the three months ended March 31, 2025, compared to $1.18 million for the same period last year, reflecting an 8% increase.
• Gross margin declined due to competitive pricing pressures and increased sales of lower margin products.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is revenue growth in BayMedica, the increased net loss and need for additional funding create uncertainty. The progress in pharmaceutical development programs is a positive, but it's still early stage.

Positives

• BayMedica's revenue increased by 8% to $1.26 million compared to the same period last year.
• General and administrative expenses decreased to $1.33 million for the three months ended March 31, 2025, from $3.75 million in the same period the previous year.
• The company is actively analyzing the potential effects and exploring strategies to mitigate the impact of tariffs on profitability in future quarters.

Negatives

• InMed Pharmaceuticals reported a net loss of $2.12 million for Q3 fiscal year 2025, an increase from the $1.72 million loss in the same period last year.
• Gross margin declined due to competitive pricing pressures and increased sales of lower margin products.
• Cash, cash equivalents, and short-term investments decreased from $6.57 million at June 30, 2024, to $4.68 million as of March 31, 2025.

Risks

• The company's cash is only expected to fund operations into the third quarter of calendar year 2025, requiring additional funding.
• The company faces competitive pricing pressures impacting gross margins.
• Changes to tariffs by the U.S. and other countries may negatively impact certain segments of the supply chain.

Future Outlook

The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the third quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses. The Company expects to seek additional funding through equity financings, debt financings and/or other capital sources, including collaborations with other companies, government contracts or other strategic transactions.

Management Comments

• We continue to advance INM-901 as a differentiated approach to treating Alzheimers disease by targeting neuroinflammation beyond conventional amyloid beta and tau-targeting strategies, and we look forward to sharing additional data in the near term.
• On the commercial side, BayMedica continues to deliver stable revenues quarter-over-quarter.
• While gross margins were impacted by increased pricing pressure, we remain focused on optimizing our product mix and improving operational efficiencies.

Industry Context

InMed is focused on developing cannabinoid-based pharmaceuticals, a growing area of interest in the pharmaceutical industry, particularly for conditions like Alzheimer's and AMD where there are high unmet medical needs. The company's focus on neuroinflammation in Alzheimer's is a differentiated approach compared to traditional amyloid beta and tau-targeting strategies.

Comparison to Industry Standards

• It is difficult to compare InMed's results directly to industry standards without knowing the specific stage of development and focus of comparable companies.
• However, companies like Amylyx Pharmaceuticals (for ALS) and Biogen (for Alzheimer's) are examples of companies that have recently brought neurological drugs to market, though their financial profiles and market capitalizations are significantly larger than InMed's.
• In the cannabinoid pharmaceutical space, companies like GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) have paved the way, but InMed's specific focus on CB1/CB2 receptors and its pipeline targeting Alzheimer's and AMD differentiate it from many other players.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for additional funding.
• Employees are likely focused on the progress of the pharmaceutical programs and the stability of BayMedica.
• Customers of BayMedica can expect continued availability of cannabinoid products.
• Suppliers may be impacted by changes to tariffs and the company's efforts to mitigate their impact.

Next Steps

• Continue advancing INM-901 for Alzheimer's disease and share additional data in the near term.
• Continue development of INM-089 for dry Age-related Macular Degeneration (AMD).
• Optimize BayMedica's product mix and improve operational efficiencies.
• Seek additional funding through equity financings, debt financings and/or other capital sources.

Key Dates

Keywords

InMed Pharmaceuticals, INM-901, INM-089, BayMedica, Alzheimer's disease, AMD, Financial Results, Q3 2025, Pharmaceuticals, Cannabinoid